Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.84 USD | +4.07% | +6.37% | +615.08% |
May. 14 | Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target | MT |
May. 02 | Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 210M |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | -60M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.14
x | P/E ratio 2025 * |
-4.17
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.73% |
1 day | +4.07% | ||
1 week | +6.37% | ||
Current month | +8.17% | ||
1 month | -1.03% | ||
3 months | +50.00% | ||
6 months | +658.59% | ||
Current year | +615.08% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Ferra
CEO | Chief Executive Officer | 49 | 21-06-16 |
Tammy Furlong
DFI | Director of Finance/CFO | - | - |
Steven Elms
CHM | Chairman | 60 | 19-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
R. Carruthers
BRD | Director/Board Member | 66 | 21-05-17 |
Timothy Clackson
BRD | Director/Board Member | 58 | 20-04-30 |
Steven Elms
CHM | Chairman | 60 | 19-04-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 3.84 | +4.07% | 1,200,303 |
24-05-23 | 3.69 | -3.15% | 313,450 |
24-05-22 | 3.81 | +2.14% | 439,902 |
24-05-21 | 3.73 | -0.27% | 286,682 |
24-05-20 | 3.74 | +3.60% | 175,318 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+615.08% | 210M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- ELEV Stock